Brought to you by 
Oncogene Science, Sankyo, MRC CC team against influenza
18 Nov 1999
Executive Summary
Sankyo (Japan's number two pharma company) gets exclusive worldwide rights to commercialize influenza products discovered in a 3-year program with Oncogene Science Inc. (novel small-molecule drug discovery) and the UK's Medical Research Council.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncogene Science, Sankyo, MRC CC team against influenza
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice